Alpha Tau Medical Ltd.
DRTSWDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Novosis(bongros/BMP-2)
Regeneration of Alveolar Tissue After Maxillary Sinus Floor Augmentation
trifluridine and tipiracil
Colorectal Neoplasms
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Novosis(bongros/BMP-2) | Phase 3 | Regeneration of Alveolar Tissue After Maxillary Sinus Floor Augmentation | - | - |
trifluridine and tipiracil | Phase 3 | Colorectal Neoplasms | - | - |
Frequently asked questions
What is in Alpha Tau Medical Ltd.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Alpha Tau Medical Ltd.'s (DRTSW) pipeline across Phase 3. Its lead program is Novosis(bongros/BMP-2) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alpha Tau Medical Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Alpha Tau Medical Ltd. (DRTSW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track DRTSW biotech catalysts?→
Add DRTSW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alpha Tau Medical Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.